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Abstract 
Growing evidence support the hypothesis that cathepsin D (catD) is related to AD but the activity of serum catD had never been assessed in 
patients with dementia. We studied the activity of serum catD in different stages of AD as well as in patients with Mild Cognitive Impairment 
(MCI) and Vascular Dementia (VD). Results do not support catD activity as a useful biomarker for dementias since we found no significant 
differences between AD stages or between AD and MCI or VD. Surprisingly we found a relation between ApoE genotype, gender and catD 
activity that reaffirm the possibility that catD might be involved in the pathogenesis of AD specifically in men carriers of ApoE4.
Introduction
Sporadic, late-onset Alzheimer’s disease (AD) is a complex dis-
ease influenced by both genetic and environmental factors. 
Many of these factors have been identified during last decades. 
However, little is known about how these factors interact.
Growing evidence point the lysosomal aspartyl protease ca-
thepsin D (catD) in AD-related processes as the activation of 
the endosomal/lysosomal system (1, 2) and the cleavage of the 
amyloid precursor protein into amyloidogenic components 
(3). Neuropathological changes in Alzheimer’s disease (AD) are 
also associated with increased expression of Apolipoprotein E 
(ApoE) and catD in astrocytes (4).
Additional evidence of the involvement of catD in AD comes 
from genetics: a non-synonymous polymorphism in the catD 
gene has been proposed to be a major risk factor for AD. 
Exonic polymorphisms of the catD gene possibly influences 
pro-catD secretion and intracellular maturation of the enzyme, 
was associated with the risk for the development of AD (5, 6, 7, 
8) although this result was not replicated in some populations (9, 
10). Others suggest that there might be a synergistic interaction 
between the the CatD T allele and the APOEepsilon4 allele in 
increasing the risk for developing AD (11, 12). Strikingly gender 
differences were found recently (13) supporting the idea that 
this polymorphism confers an increased risk for AD in men but 
not in women.
Nevertheless, the enzymatic activity of serum catD had never 
been assessed in patients with dementia. We aimed to study 
the activity of serum catD in different stages of AD as well as 
in patients with Mild Cognitive Impairment (MCI) and Vascular 
Dementia (VD) in order to evaluate if this parameter could be 
considered a potential biomarker for AD.
Subjects and Methods
This project has been approved by the Research and Ethics 
Committees of the Hospital Universitario Central de Asturias 
(HUCA). Informed consent was obtained from all individuals or 
their guardians.
All individuals assessed at the HUCA-Dementia Unit from Janu-
ary 2003 to December 2005 meeting the inclusion criteria were 
invited to join the study.
Patients
Inclusion criteria
Patients suffering from one of the next conditions: MCI accord-
ing to Petersen’s criteria (14), AD according to the NINDS-ADRA 
criteria (15), and VD according to the NINDS-AIREN criteria (16).
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Exclusion criteria
Patients suffering from other conditions causative of cognitive 
impairment including cancer, hydrocephalus, infectious, meta-
bolic or toxic disease. Patients with renal or hepatic dysfunction 
(often associated with abnormal levels of plasmatic proteins).
Controls
Individuals without any central nervous system disorder and 
ageing more than 60 years old were included as controls. Con-
trols were recruited among healthy people matching the age 
of patients, mainly the spouses of the patients included, or pa-
tients studied in our department for peripheral nervous system 
diseases.
Clinical Assessment
All patients were studied with neuroimaging and full neuro-
psychological assessment following the AAN recommenda-
tions (17). Neuropsychological assessment included the “Test 
Barcelona Abreviado” (18) in all patients as well as other tests 
depending on each patient’s profile. The Barthel Index (19) was 
also performed in all patients.
ApoE genotype was determined in all cases of AD: genomic 
DNA was obtained from blood following a salting-out method 
(20) and ApoE genotyping was performed as previously de-
scribed (21).
The staging of the disease was performed following the GDS-
FAST criteria (22): mild AD: GDS4, moderate AD: GDS5 and severe 
AD: GDS6.
Immunoassay
Plasma sample acquisition, storage and laboratory conditions 
were identical for all specimens used in the study. We used 
the MBL kit for cathepsin-D activity (Woburn, MA) which is a 
fluorescence-based assay that measures the free AFC (amino-
4-trifluoromethyl coumarin) released after cleavage of the pre-
ferred cathepsin-D substrate sequence RGFFP labelled with AFC. 
To this end serum samples were added to the synthetic sub-
strate in fluorescence validate black 96-wells microtiter plates 
(BD FalconTM, Becton Dickinson) and incubated at 37ºC for 2 
hours. Fluorescence was quantified in a Cary Eclipse Fluores-
cence Spectrophotometer (Varian Ibérica S.A., Madrid) using 
a 328 nm excitation filter and 460 nm emission filter. Results 
were expressed by the relative fluorescence units (RFU) per ml 
of serum.
Statistics
A Chi-square test was performed to study gender distribution 
differences between controls and patients. A T-Student test was 
performed to assess differences in age between controls and 
patients. ANOVA tests were performed to asses the differences 
in catD activity between groups. Chi-square tests were applied 
to assess whether catD activity is associated to the fact of be-
ing carrier of the E4 allele. Finally, the Mann–Whitney U test was 
used for assessing differences related both to gender and ApoE 
genotype.
Results
Sample description
We studied 40 controls and 149 patients. Sixteen patients suf-
fered from MCI, 25 from VD and 108 from AD. Patients with AD 
were in different stages: 52 mild AD, 38 moderate AD and 18 
severe AD. The mean age was 77,04 (std. dev.: 8,38) and there 
were no significant differences between groups (p=0.744). One 
hundred and 2 subjects were female and 47 male; there were 
no significant differences between groups (p=0.216), although 
in patients with AD there were a higher rate of female subjects 
than in other groups. Finally, 38% of patients with AD were car-
rier of the ApoE4 allele.
CatD activity
The activity of catD was similar in all groups (Table 1). The mean 
activity in controls was 659,83 units/ml. There were no signifi-
cant differences between groups (p=0.252).The higher activity 
was found in patients with VD (706,99 units/ml) and the lower in 
patients with severe AD (587,35 units/ml) though this difference 
was not significant (p=0.105). There is no correlation between 
the severity of disease in AD and the catD activit
Table 1. CatD activity (units/ml) measured by relative 
fluorescence in units/ml.
Diagnostic 
groups
Mean N Std. Dev.
Control 659,84 40 401,35
mild AD 648,92 52 435,04
moderate AD 674,44 38 358,31
severe AD 587,36 18 107,40
MCI 676,14 16 277,59
VD 706,99 25 379,45
Total 660,48 189 369,45
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Relation ApoE genotype-catD activity
When we studied the activity in patients with AD, those who 
were carriers of one E4 allele had lower activity (596,78 units/
ml) than those without E4 allele (702,95 units/ml), though this 
difference did not reach statistical significance (p=0.126). This 
trend was present for all disease stages, as shown in table 2.
On the other hand being carrier of two E4 allele did not associ-
ate with lower activity than being carrier of just one E4 allele 
(p=0,416).
Relation gender-catD activity
When we specifically compared the catD activity by gender, 
in both ApoE4-carriers and not carriers, we found a significant 
difference (p=0,037) only in the group of ApoE4 carriers: men 
showed a lower activity (mean: 542,27 units/ml – SD: ± 74,51) 
than women (mean: 639,36 units/ml – SD: ± 103,84) (Figure 1).
Table 2. CatD activity (units/ml) in the three AD stages in E4 
and no E4 carriers.
 No E4 E4
mild AD 704 585
moderate AD 730 652
severe AD 582 547
Discussion
Lysosomal impairment is involved in AD pathogenesis and can 
be detected not only in the CNS but also at a peripheral level 
(1, 23). This involvement may happen through catD. In fact catD 
seems to be involved in the proteolysis of ApoE and probably 
contributes to the generation of ApoE fragments previously im-
plicated in AD pathology (24). One of the studies presented at 
the 5th General Meeting of the International Proteolysis Society 
that address enzymatic mechanisms for producing neurotoxic 
beta-amyloid (Abeta) peptides describes the poor kinetics of 
BACE 1 for cleaving the wild-type (WT) beta-secretase site of 
APP found in most AD patients. They showed that cathepsin D 
displays BACE 1-like specificity and cathepsin D is 280-fold more 
abundant in human brain than BACE 1 (25).
We assessed the activity of serum catD in controls, AD, MCI and 
VD and did not found any significant association with the diag-
nosis of AD. However, there is a correlation with the genotype 
E4: at the three stages of the disease the activity is lower (not to 
the point of statistical significance) in those patients carriers of 
at least one apoE4 allele. This suggests that the ApoE genotype 
influences the activity of serum catD and in turn it can be more 
or less amyloidogenic. This finding is supported by genetic stud-
ies (11, 12). As the risk of AD in population is higher between E4 
carriers one may infer that low catD activity might contribute 
to amyolidogenic deposits. In this line, Cathepsin D was found 
to be involved in the intracellular clearance of aggregatable Aβ 
(26).
Surprisingly, we also found a significant lower activity in men 
carriers of ApoE4, than in women or men who were not ApoE4 
carriers. This finding also links with the results of genetic studies 
since the single nucleotide polymorphism rs17571 of the catD 
gene confers an increased risk for AD in men but not in women 
(13). These facts support the hypothesis of gender-specific dif-
ferences in the pathogenesis of AD (27).
Further studies, assessing the interaction between gender, ApoE 
and catD genes polymorphisms and catD activity are needed to 
fully understand their relation.
Conclusion
In the light of our results, the activity of serum catD does not 
seem to be a useful biomarker to distinguish between AD and 
VD or to monitor the progression of the disease, but these re-
sults confirm the possibility that the activity of serum catD in 
patients with AD is related to the ApoE genotype and gender 
and therefore might contribute to the pathogenesis of the dis-
ease only in a concrete subpopulation of patients: men carriers 
of ApoE4.Figure 1. Comparison of catD activity (units/ml) in men and 
women in carriers and not carriers of ApoE4.
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